Neuronetics amended its report solely to refile a legal opinion and consent that superseded and replaced the originals. The underlying offering covered 18,750,000 common shares at $1.60 per share.
STIM · Neuronetics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Therefore, substantial doubt exists about the Company’s ability to continue as a going concern. However, at this time, these actions do not fully mitigate the risk related to compliance with the revenue covenant for the March 31, 2027 period.”View the 10-Q filed Nov 4, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Neuronetics, Inc. priced an offering of 18,750,000 common shares at $1.60 per share, expecting approximately $27.7 million in net proceeds. It will use part of the proceeds to repay Perceptive Credit Holdings IV, LP term loans and for general corporate purposes.
Neuronetics, Inc. entered Amendment No. 6 on November 5, 2026, modifying revenue covenants, conditional on a prepayment of no less than $15,000,000. Unless conditions are satisfied or waived by November 30, 2026, the amendment automatically terminates.
Neuronetics reported third-quarter revenue of $42.0 million, up 13%, and a $1.6 million net loss, but projected March 31, 2027 trailing revenue below its covenant minimum creates substantial going-concern doubt.
Neuronetics reported third-quarter 2026 revenue of $42.0 million, up 12.5%, and adjusted EBITDA of $1.9 million versus $(4.7) million last year. Net loss was $1.6 million, and full-year revenue guidance remained $160 million and $164 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$6.33M | Six months ended June 30 | — |
| EBITDA non-GAAP | -$9.55M | Six months ended June 30 | — |
| Net cash used in operations and investing | $1.4M | second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STIM
this stock
Neuronetics, Inc.
|
$108.04M | +0.7% | +30.5% | — | 8.6% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 25
Neuronetics amended its report solely to refile a legal opinion and consent that superseded and replaced the originals. The underlying offering covered 18,750,000 common shares at $1.60 per share.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STIM | -35.4% | -26.3% | +13.9% | -38.2% | +0.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -37.9% | -25.1% | +13.4% | -38.0% | -9.9% |